Journal Article Review Ppublish
PubMed: 39843757 DOI: 10.1007/s40265-024-02107-3
The Future of Microbiome Therapeutics.
Drugs 85(2):117-125
Authors: Milena Pitashny, Inbar Kesten, Dima Shlon, Dana Ben Hur, Haggai Bar-Yoseph
Affiliations
- Clinical and Research Microbiome Center, Rambam Health Care Campus, Haifa, Israel.
- Rappaport Faculty of Medicine, Technion, Haifa, Israel.
- Internal Medicine D, Rambam Health Care Campus, Haifa, Israel.
- Internal Medicine H, Rambam Health Care Campus, Haifa, Israel. Department of Gastroenterology, Rambam Health Care Campus, HaAliya HaShniya St 8, 3109601, Haifa, Israel.
- Clinical and Research Microbiome Center, Rambam Health Care Campus, Haifa, Israel.
- Department of Gastroenterology, Rambam Health Care Campus, HaAliya HaShniya St 8, 3109601, Haifa, Israel.
- Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Abstract
The human microbiome exerts profound influence over various biological processes within the body. Unlike many host determinants, it represents a readily accessible target for manipulation to promote health benefits. However, existing commercial microbiome-directed products often exhibit low efficacy. Advancements in technology are paving the way for the development of novel microbiome therapeutics, across a wide range of indications. In this narrative review, we provide an overview of state-of-the-art technologies in late-stage development, examining their advantages and limitations. By covering a spectrum, from fecal-derived products to live biotherapeutics, phage therapy, and synthetic biology, we illuminate the path toward the future of microbiome therapeutics.
MeSH
Pharmaceutical Preparations, Drug Therapy, Therapeutics